NCT00841152 (BAGvsTCP) is a clinical trial of Bioactive glass in Bone Neoplasm, sponsored by Turku University Hospital.

Who is sponsoring NCT00841152?

NCT00841152 is sponsored by Turku University Hospital.

What drugs are being tested in NCT00841152?

Interventions in NCT00841152: Bioactive glass, Beta-tricalcium phosphate (ChronOs), Autograft, Allograft (frozen femoral head).

What condition does NCT00841152 study?

NCT00841152 studies Bone Neoplasm.

Is NCT00841152 still recruiting?

NCT00841152 is currently completed. Last updated 12 March 2021.

Last reviewed 2021-03-12 · How we verify

NCT00841152: BAGvsTCP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects

Completed Last updated 12 March 2021

What this trial tests

trial testing Bioactive glass in Bone Neoplasm in 120 participants. Completed in 1 December 2018.

Timeline

1 March 2009

Primary endpoint
1 February 2014

1 December 2018

Quick facts

Lead sponsor	Turku University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 March 2009
Primary completion	1 February 2014
Estimated completion	1 December 2018
Sites	5 locations across Finland

Drugs / interventions tested

Bioactive glass — full drug profile →
Beta-tricalcium phosphate (ChronOs)
Autograft
Allograft (frozen femoral head)

Conditions studied

Bone Neoplasm — all drugs for Bone Neoplasm →

Sponsor

Turku University Hospital

Who can join

18 and older, any sex, with Bone Neoplasm. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Stratum I: Hand-grip strength test
Time frame: 3 months
Hand and finger grip strength measured by a standard device
Stratum II: Healing of cortical bone window based on CT scan evaluation
Time frame: 6 months
CT-evaluation of cortical defect healing

Sponsor's own description

This study is designed to perform a head-to-head comparison of two synthetic ceramic bone graft substitutes, bioactive glass (BAG) and beta-tricalcium phosphate (TCP), in filling of contained bone defects following surgical evacuation of benign bone tumor or tumor-like conditions. Based on the investigators' previous preclinical research and an ongoing single-center randomized clinical trial on bioactive glass filling, the investigators expect BAG filling to be more efficient compared to TCP in promotion of defect healing and functional recovery after surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Poly(lactic-<i>co</i>-glycolic acid)-based composite bone-substitute materials.
Zhao D, Zhu T, Li J, Cui L, et al · · 2021 · cited 238× · PMID 32954053 · DOI 10.1016/j.bioactmat.2020.08.016

Verify or expand the search:

Other trials of Bioactive glass

Trials testing the same drug.

NCT07063433 — Effect of Gluma and Bioactive Glass Desensitizers in Treatment of Dentin Hypersensitivity in Cervical Non-Carious Lesion · NA · completed
NCT02796911 — Comparative Study of Different Bone Grafts in Accelerating Tooth Movement · NA · completed
NCT04737590 — Bioactive Glass or Allogenic Bone in Pediatric Bone Cysts · NA · unknown

Other recruiting trials for Bone Neoplasm

Currently open trials in the same condition.

NCT04394052 — Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II · recruiting
NCT04307914 — Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases · NA · active not recruiting
NCT03442465 — Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas · recruiting

Other Turku University Hospital trials

Trials by the same sponsor.

NCT07488494 — Effective Implementation of the Physical Activity and Motor Skills Intervention for 3-6-year-old Children With Cancer (E · NA · not yet recruiting
NCT07316868 — Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery · NA · not yet recruiting
NCT07306000 — Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development · NA · recruiting
NCT07272824 — Usability Study of Gestational and Postpartum Weight Management Program · recruiting
NCT07310472 — Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00841152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Turku University Hospital
Last refreshed: 12 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00841152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing